Sulitzeanu D, Asaf O, Biran S, Brufman G, Gilead Z
Isr J Med Sci. 1981 Sep-Oct;17(9-10):869-73.
Sera of patients with breast cancer were tested for the presence of immune complexes by a complement-consumption assay. To increase the concentration of immune complexes and thus improve the chances of their detection, sera were first ultracentrifuged and the sedimented material was assayed. Sera were considered to be positive if they consumed at least 75% of the hemolytic activity under the conditions of the test. Of the 60 patients tested, 45% were positive as compared with 13.5% positive sera among health blood bank donors. The presence of immune complexes could not be correlated with the extent of disease, the age of the patients, treatment or lack of treatment at the time of the test, or the time that had elapsed since diagnosis. In a few control tests, treatment of samples with DNase had no effect on their anticomplementary activity, whereas reduction with 2-mercaptoethanol abrogated the activity. These results strengthened the assumption that the substances binding complement were indeed immune complexes.
通过补体消耗试验检测乳腺癌患者血清中免疫复合物的存在情况。为了提高免疫复合物的浓度从而增加检测到它们的几率，先对血清进行超速离心，然后对沉淀物质进行检测。如果血清在试验条件下消耗了至少75%的溶血活性，则被认为是阳性。在检测的60名患者中，45%呈阳性，而健康血库供者中阳性血清的比例为13.5%。免疫复合物的存在与疾病程度、患者年龄、检测时的治疗或未治疗情况，或自诊断以来经过的时间均无关联。在一些对照试验中，用脱氧核糖核酸酶处理样品对其抗补体活性没有影响，而用2-巯基乙醇还原则消除了该活性。这些结果强化了这样一种假设，即结合补体的物质确实是免疫复合物。
